新华制药：甲钴胺片获药品补充申请批准通知书

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the supplementary application of Mecobalamin tablets, allowing the transfer of the marketing authorization holder [1] Company Summary - The transaction does not require approval from the company's board of directors or shareholders, as it does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1] - Mecobalamin tablets are indicated for peripheral neuropathy and are listed as a Class B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Industry Summary - In 2023, the sales revenue of Mecobalamin tablets in Chinese public medical institutions is approximately RMB 1.431 billion [1]